

RATIONALE

Adeno-pituitary tumour represents a complex disease, with a wide spectrum of clinical manifestations, according to the ability of secreting different hormones or pro-hormones and of invading the neighbouring anatomical structures, such as the same pituitary gland, the optical chiasm, the cavernous sinus, the bone, the third ventricle and the ventricular system. In the most recent years, a better definition of these neoplasia was researched in order to identify biomarkers able to predict the natural history of adeno-pituitary tumour and their responsiveness to the different treatments.

Until now, the classifications of the neoplasms arising from adeno-hypophysial cells have been misleading because of their poor reproducibility and their weak ability in predicting the aggressiveness, the prognosis, and the outcome of these neoplasia. The 2004 WHO classification distinguished pituitary adenoma in typical and atypical ones according to the detection of mitoses and according to the expression of Ki-67 or p53. The 2004 WHO classification however failed in identifying pituitary tumours refractory to medical, surgical or radiation therapies or able to regrowth or to metastasize. Similarly, the new 2017 WHO classification lacks in defining the prognosis of pituitary neoplasia. Invasive, recurrent and proliferative pituitary neoplasia cause significant morbidity, in particular in cases of persistence hormonal hyper-secretion. Both long term hormonal hyper-secretion and hypopituitarism, in absence of an adequate hormonal replacement therapy, are associated to increased morbidity and mortality for their systemic complications.

Therefore, recently, adeno-pituitary tumours were included in neuroendocrine tumours (NETs). This new terminology of pituitary neuroendocrine tumor (PitNET) may reflect better the potential for aggressiveness and malignant behaviour and of these neoplasia. Anyway a consensus on PitNETs was not yet reached.

On this basis, in the recent years, a wide number of research investigated the genetic, molecular and biological features of PitNETs, in order to predict the clinical behaviour of these neoplasia and to personalize the treatments in non-secreting and secreting tumors as prolactinoma, acromegaly, Cushing disease. The current event has the aim of updating participants on the latest biological, genetic and clinical acquisitions on PitNET and on their impact in the management of PitNET affected patients according to the new knowledge, that requires a close clinical collaboration between pathologists, neurosurgeons and endocrinologists.

The meeting is part of the teaching activities of the Master Degree in Diagnosis and Treatment of pituitary disease (2021) - Faculty of Medicine, Università Cattolica del Sacro Cuore, Rome.

DIRECTOR Prof. ALFREDO PONTECORVI

Professor of Endocrinology

Fondazione Policlinico Universitario A. Gemelli
Università Cattolica del Sacro Cuore, Rome

SEDE

📍 Hotel Donna Camilla Savelli - Via Garibaldi 27, 00153 Roma RM

RESPONSABILE SCIENTIFICO

Prof.ssa Laura De Marinis

Coordinatore Scientifico del Master Universitario di II Livello in diagnosi e terapia delle patologie ipotalamo ipofisarie - Policlinico Universitario A. Gemelli, Roma

PROVIDER E SEGRETERIA ORGANIZZATIVA



Provider Standard accreditato presso la Commissione Nazionale ECM - ID 680

📍 Via Flaminia, 54 | 00196 Roma

📞 Tel. 06 4061370 | Fax 06 3242600 | 📩 E-Mail: info@dotcomeventi.com | www.dotcomeventi.com

ISCRIZIONI

Per iscriversi collegarsi al sito www.dotcomeventi.com

Per ragioni organizzative legate all'emergenza sanitaria in atto è obbligatoria la pre-iscrizione

La partecipazione all'evento è gratuita

ATTENZIONE! Sulla base della normativa vigente, per la partecipazione in presenza è necessario un GREEN PASS in corso di validità.

ECM 680 - 333893

Assegnati n. 10 crediti formativi ECM

L'evento rientra nel Piano Formativo ECM anno 2021 della DOTCOM Srl ed è rivolto alle figure professionali di:

- **Medico - Chirurgo:** Anatomia Patologica, Chirurgia Generale, Endocrinologia, Gastroenterologia, Genetica Medica, Malattie Metaboliche e Diabetologia, Medicina Interna, Medicina Nucleare, Neurorochirurgia, Neuroradiologia, Oftalmologia, Otorinolaringoiatria, Patologia Clinica (Laboratorio di Analisi Chimico- Cliniche e Microbiologia), Radiodiagnistica, Radioterapia.
- **Infermiere**

OBIETTIVO FORMATIVO

Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura

Con la sponsorizzazione non condizionante di



Arwork: Simona Reniè - Stampa: Arti Grafiche Vincenò Srl

PitNETs and aggressive pituitary adenomas are two sides of the same coin?

Con il patrocinio di

Gemelli



Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore



sie Società Italiana
Endocrinologia

RESPONSABILE SCIENTIFICO
Laura De Marinis

ROME
25th 26th
November 2021

Hotel Donna Camilla Savelli
Via Garibaldi 27 Roma

1st DAY | Thursday, 25th November 2021

Fuori accreditamento ECM

PRE-MEETING SESSION

Malattia di Cushing, problematiche diagnostiche e terapeutiche nei Casi Clinici complessi

Coordinatori: A. Bianchi, S. Chiloiro

10.00 - 12.30

SESSIONE I: Focus on: problemi diagnostici e terapeutici

Moderatori: A. Bianchi, F. Doglietto, M. Poggi, A. Scoppola

Diagnosi neuroradiologica e radiologica interventistica nella Malattia di Cushing - Andrea Alexandre

Approccio neurochirurgico nella Malattia di Cushing - Pier Paolo Mattogno

La terapia antiosteoporotica nella Sindrome di Cushing - Anna Maria Formenti

SESSIONE II: Esperienze a confronto sui casi clinici complessi: problematiche diagnostiche, scelte terapeutiche e terapie innovative

Moderatori: M. Appetecchia, R. Baldelli, A. Bianchi, P. Gargiulo, A.M. Isidori, M. Poggi, A. Stigliano

Azienda Ospedaliero Universitaria Sant'Andrea - Roberta Maggio

Azienda Ospedaliera San Camillo Forlanini - Marta Franco

I.R.C.S.S. Istituti Fisioterapici Ospedalieri - Marilda Mormando

Azienda Ospedaliero-Universitaria Policlinico Umberto I - Valeria Mercuri

Azienda Ospedaliero-Universitaria Policlinico Umberto I - Dario De Alcubierre

Fondazione Policlinico Universitario Agostino Gemelli - Laura Rossi

12.30 Registration

13.30 Introduction: L. De Marinis

Welcome Speech: L. Festa, A. Giustina, F. Grimaldi, D. Lauro, A. Lenzi, C. Motta, A. Pontecorvi

PRESIDENTIALE LECTURE

Chairmen: A. Lenzi, A. Pontecorvi

14.00 Pituitary neoplasia nomenclature (Panomen) - A. Giustina

I SESSION: New molecular knowledge and acquisitions on PitNETs: an update

Chairman: M.C. Zatelli

14.20 Universal nomenclature of neuroendocrine neoplasia: news from the WHO - G. Rindi

14.40 How to standardize the diagnostic approach to pituitary neuroendocrine tumours (PitNETs) - C. Villa

15.00 Challenging tumor with or without genes - M. Korbonits

15.30 Pituitary tumors microenvironment: clinical implications - G. Raverot

16.00 Discussion on topics

II SESSION

Chairmen: G. Arnaldi, E. De Menis, S. Grottoli

16.30 Precision Medicine: new perspectives for the treatment of GH-secreting tumors
The MISS study - A. Berton

16.50 Pituitary proteomics - D. Milardi

17.10 Combining temozolamide and radiotherapy in aggressive pituitary tumors? A. M. Isidori

17.30 Discussion on topics

18.00 Conclusions

12.10 The point of view of the neurosurgeon - F. Doglietto

12.30 The point of view of the radiotherapist - C. Mazzarella, G. Minniti

12.50 The point of view of the bone metabolism specialist - S. Frara, A. Spada

13.10 Discussion on topics

13.30 Lunch

IV SESSION: Round Table

Pituitary adenomas Vs PitNETs in the real life: impact on endocrine management

Chairman: A. Mangiola

14.30 ACTH secreting adenoma Vs PitNET - R. Pivonello
Discussant: R. Baldelli

14.50 GH secreting adenoma Vs PitNET - A. Bianchi
Discussant: F. Doglietto

15.10 Not secreting adenoma Vs PitNET - F. Dassie
Discussant: A. Scoppola

15.30 Prolactin secreting adenoma Vs PitNET - S. Chiloiro
Discussant: M. Poggi

15.50 Discussion on topics

16.10 Closing remarks

FACULTY

Giorgio Arnaldi, Fano
Roberto Baldelli, Roma
Rocco Bellantone, Roma
Antonella Giampietro, Roma
Alessandro Maria Berton, Torino
Antonio Bianchi, Roma
Carmelo Caldarella, Roma
Salvatore Cannavò, Messina
Ettore Domenico Capoluongo, Roma
Felipe Casanueva, Madrid
Sabrina Chiloiro, Roma
Francesca Dassie, Padova
Laura De Marinis, Roma
Ernesto De Menis, Treviso
Francesco Doglietto, Brescia
Lucia Festa, Roma
Stefano Frara, Torino
Federico Gatto, Genova

Marco Gessi, Roma
Ezio Ghigo, Torino
Cecilia Motta, Roma
Rosario Pivonello, Napoli
Maurizio Poggi, Roma
Alfredo Pontecorvi, Roma
Silvia Grottoli, Torino
Andrea Isidori, Roma
Guido Rindi, Roma
Carla Scaroni, Padova
Alessandro Scoppola, Roma
Davide Lauro, Roma
Antonio Spada, Roma
Tommaso Tartaglione, Roma
Vincenzo Toscano, Roma
Annunziato Mangiola, Pescara
Giovanna Mantovani, Milano
Ciro Mazzarella, Roma
Gherardo Mazzotti, Mantova
Domenico Milardi, Roma

Giuseppe Minniti, Roma
Cecilia Motta, Roma
Rosario Pivonello, Napoli
Maurizio Poggi, Roma
Alfredo Pontecorvi, Roma
Silvia Grottoli, Torino
Andrea Isidori, Roma
Guido Rindi, Roma
Carla Scaroni, Padova
Alessandro Scoppola, Roma
Davide Lauro, Roma
Antonio Spada, Roma
Tommaso Tartaglione, Roma
Vincenzo Toscano, Roma
Chiara Maria Villa, Parigi
Maria Chiara Zatelli, Ferrara
Marcella Zollino, Roma
Paolo Zuppi, Roma

2nd DAY | Friday, 26th November 2021

LECTURE

Chairmen: V. Toscano, P. Zuppi

08.40 GH replacement therapy in patients treated for PitNET: case series and review of literature
A. Giampietro

LECTURE

Chairmen: E. Ghigo, P. Maffei

09.00 Role of pituitary center of excellence - F. Casanueva

III SESSION: Round Table

Role of pituitary center of excellence in defining the nomenclature of pituitary neoplasia

Part 1

Chairmen: M. L. Jaffrain-Rea, G. Mantovani, M. Zollino

09.30 The point of view of the geneticist - E. Capoluongo

09.50 The point of view of the pathologist - M. Gessi

10.10 The point of view of the translational medicine expert - F. Gatto

10.30 Aggressive pituitary tumors: influence on bone metabolism - G. Mazzotti

10.50 Discussion on topics

11.10 Coffee break

Part 2

Chairmen: S. Cannavò, C. Scaroni

11.30 The point of view of the radiologist - T. Tartaglione

11.50 The point of view of the nuclear medicine expert - C. Caldarella